Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Sionna Therapeutics, Inc.NASDAQ: SION
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $154K fell 3.1% year over year, behind the +36.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 69.4% from the prior quarter.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.1% toward the trailing-twelve-month pace of +36.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- (3.05M) USD
- Year-over-year change
- -556.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.05M) | -556.9% |
| FY2024 | 2024-12-31 | 668K | +14.6% |
| FY2023 | 2023-12-31 | 583K | +377.9% |
| FY2022 | 2022-12-31 | 122K | — |
Depreciation & Amortization vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 depreciation & amortization of $904K is the 10th largest of the 11 companies compared; the peer median is $3.74M.
- Its year-over-year change of +36.8% is the 3rd highest of 11, against a peer median of +6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M | -7.6% | -4.5% | 47.4% | |
| LTM Mar 2026 | $12.47M | +3.0% | -1.4% | 4.0% | |
| LTM Jun 2026 | $10.32M | +18.9% | +92.7% | — | |
| LTM Sep 2026 | $9.03M | -29.4% | -2.5% | 3.4% | |
| LTM Sep 2026 | $3.76M | +35.4% | +67.3% | — | |
| LTM Sep 2026 | $3.73M | +10.4% | +5.3% | 3333.9% | |
| LTM Mar 2026 | $3.37M | +51.2% | +38.8% | 0.8% | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
| LTM Mar 2026 | $1.98M | -3.3% | +34.1% | 9.2% | |
| LTM Mar 2026 | $904K | +36.8% | — | — | |
| LTM Jun 2026 | $652K | +130.4% | — | — | |
| Peer median (excluding SION) | $3.74M | +6.7% | +5.3% | 9.2% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.